Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Accounts Payables (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Accounts Payables for 6 consecutive years, with $7.7 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables fell 45.34% to $7.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.7 million through Dec 2025, down 45.34% year-over-year, with the annual reading at $7.7 million for FY2025, 45.34% down from the prior year.
  • Accounts Payables for Q4 2025 was $7.7 million at Relay Therapeutics, up from $2.8 million in the prior quarter.
  • The five-year high for Accounts Payables was $14.8 million in Q2 2023, with the low at $2.8 million in Q3 2025.
  • Average Accounts Payables over 5 years is $8.7 million, with a median of $8.2 million recorded in 2021.
  • The sharpest move saw Accounts Payables soared 243.99% in 2023, then tumbled 59.92% in 2025.
  • Over 5 years, Accounts Payables stood at $8.3 million in 2021, then increased by 27.82% to $10.6 million in 2022, then dropped by 12.92% to $9.2 million in 2023, then surged by 53.05% to $14.1 million in 2024, then crashed by 45.34% to $7.7 million in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $7.7 million, $2.8 million, and $5.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.